204 related articles for article (PubMed ID: 23792175)
1. A novel retro-inverso peptide is a preferential JNK substrate-competitive inhibitor.
Ngoei KR; Catimel B; Milech N; Watt PM; Bogoyevitch MA
Int J Biochem Cell Biol; 2013 Aug; 45(8):1939-50. PubMed ID: 23792175
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel JNK (c-Jun N-terminal kinase) inhibitory peptide.
Ngoei KR; Catimel B; Church N; Lio DS; Dogovski C; Perugini MA; Watt PM; Cheng HC; Ng DC; Bogoyevitch MA
Biochem J; 2011 Mar; 434(3):399-413. PubMed ID: 21162712
[TBL] [Abstract][Full Text] [Related]
3. c-Jun N-terminal kinase binding domain-dependent phosphorylation of mitogen-activated protein kinase kinase 4 and mitogen-activated protein kinase kinase 7 and balancing cross-talk between c-Jun N-terminal kinase and extracellular signal-regulated kinase pathways in cortical neurons.
Repici M; Mare L; Colombo A; Ploia C; Sclip A; Bonny C; Nicod P; Salmona M; Borsello T
Neuroscience; 2009 Mar; 159(1):94-103. PubMed ID: 19135136
[TBL] [Abstract][Full Text] [Related]
4. Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3alpha1.
Ember B; Kamenecka T; LoGrasso P
Biochemistry; 2008 Mar; 47(10):3076-84. PubMed ID: 18269248
[TBL] [Abstract][Full Text] [Related]
5. Selectivity of docking sites in MAPK kinases.
Bardwell AJ; Frankson E; Bardwell L
J Biol Chem; 2009 May; 284(19):13165-73. PubMed ID: 19196711
[TBL] [Abstract][Full Text] [Related]
6. Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells.
Yu W; Liao QY; Hantash FM; Sanders BG; Kline K
Cancer Res; 2001 Sep; 61(17):6569-76. PubMed ID: 11522656
[TBL] [Abstract][Full Text] [Related]
7. Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation.
Gallo A; Cuozzo C; Esposito I; Maggiolini M; Bonofiglio D; Vivacqua A; Garramone M; Weiss C; Bohmann D; Musti AM
Oncogene; 2002 Sep; 21(42):6434-45. PubMed ID: 12226747
[TBL] [Abstract][Full Text] [Related]
8. Identification of the critical features of a small peptide inhibitor of JNK activity.
Barr RK; Kendrick TS; Bogoyevitch MA
J Biol Chem; 2002 Mar; 277(13):10987-97. PubMed ID: 11790767
[TBL] [Abstract][Full Text] [Related]
9. A docking site in MKK4 mediates high affinity binding to JNK MAPKs and competes with similar docking sites in JNK substrates.
Ho DT; Bardwell AJ; Abdollahi M; Bardwell L
J Biol Chem; 2003 Aug; 278(35):32662-72. PubMed ID: 12788955
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of a substrate selective p38alpha inhibitor.
Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
[TBL] [Abstract][Full Text] [Related]
11. Effector peptides from glutathione-S-transferase-pi affect the activation of jun by jun-N-terminal kinase.
Adler V; Pincus MR
Ann Clin Lab Sci; 2004; 34(1):35-46. PubMed ID: 15038666
[TBL] [Abstract][Full Text] [Related]
12. Differential targeting of the stress mitogen-activated protein kinases to the c-Jun dimerization protein 2.
Katz S; Aronheim A
Biochem J; 2002 Dec; 368(Pt 3):939-45. PubMed ID: 12225289
[TBL] [Abstract][Full Text] [Related]
13. Active, phosphorylation-dependent MAP kinases, MAPK/ERK, SAPK/JNK and p38, and specific transcription factor substrates are differentially expressed following systemic administration of kainic acid to the adult rat.
Ferrer I; Blanco R; Carmona M; Puig B; Domínguez I; Viñals F
Acta Neuropathol; 2002 Apr; 103(4):391-407. PubMed ID: 11904760
[TBL] [Abstract][Full Text] [Related]
14. JNK1/c-Jun and p38 alpha MAPK/ATF-2 pathways are responsible for upregulation of Fas/FasL in human chronic myeloid leukemia K562 cells upon exposure to Taiwan cobra phospholipase A2.
Chen KC; Chiou YL; Chang LS
J Cell Biochem; 2009 Oct; 108(3):612-20. PubMed ID: 19670268
[TBL] [Abstract][Full Text] [Related]
15. c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia.
Waetzig V; Czeloth K; Hidding U; Mielke K; Kanzow M; Brecht S; Goetz M; Lucius R; Herdegen T; Hanisch UK
Glia; 2005 May; 50(3):235-46. PubMed ID: 15739188
[TBL] [Abstract][Full Text] [Related]
16. Designed ankyrin repeat proteins (DARPins) as novel isoform-specific intracellular inhibitors of c-Jun N-terminal kinases.
Parizek P; Kummer L; Rube P; Prinz A; Herberg FW; Plückthun A
ACS Chem Biol; 2012 Aug; 7(8):1356-66. PubMed ID: 22568706
[TBL] [Abstract][Full Text] [Related]
17. Selective targeting of MAPK family kinases JNK over p38 by rationally designed peptides as potential therapeutics for neurological disorders and epilepsy.
Zhuo ZH; Sun YZ; Jin PN; Li FY; Zhang YL; Wang HL
Mol Biosyst; 2016 Jul; 12(8):2532-40. PubMed ID: 27263470
[TBL] [Abstract][Full Text] [Related]
18. Interacting JNK-docking sites in MKK7 promote binding and activation of JNK mitogen-activated protein kinases.
Ho DT; Bardwell AJ; Grewal S; Iverson C; Bardwell L
J Biol Chem; 2006 May; 281(19):13169-13179. PubMed ID: 16533805
[TBL] [Abstract][Full Text] [Related]
19. Selective interaction of JNK protein kinase isoforms with transcription factors.
Gupta S; Barrett T; Whitmarsh AJ; Cavanagh J; Sluss HK; Dérijard B; Davis RJ
EMBO J; 1996 Jun; 15(11):2760-70. PubMed ID: 8654373
[TBL] [Abstract][Full Text] [Related]
20. Beta 1 integrin- and proteoglycan-mediated stimulation of T lymphoma cell adhesion and mitogen-activated protein kinase signaling by thrombospondin-1 and thrombospondin-1 peptides.
Wilson KE; Li Z; Kara M; Gardner KL; Roberts DD
J Immunol; 1999 Oct; 163(7):3621-8. PubMed ID: 10490955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
